Generalizable systems pharmacology model of bispecific T-cell engager (BiTE (R)) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients

Chudasama Vaishali L.; Harrold John M.; Dos Santos Cedric; Rock Dan; Kischel Roman; Klinger Matthias; Melhem Murad

首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Generalizable systems pharmacology model of bispecific T-cell engager (BiTE (R)) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients

【24h】

Generalizable systems pharmacology model of bispecific T-cell engager (BiTE (R)) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients

机译：双特异性T细胞参与者（咬合（r））抗体构建体的概括性系统药理学模型：非霍奇金淋巴瘤（NHL）患者的Blinatumomab（CD19 / CD3）的病例研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2018年第suppla期|共2页
作者
Chudasama Vaishali L.; Harrold John M.; Dos Santos Cedric; Rock Dan; Kischel Roman; Klinger Matthias; Melhem Murad;
展开▼
作者单位

Clin Pharmacol Modeling &

Simulat Thousand Oaks CA USA;

Pharmacokinet &

Drug Metab PKDM Seattle WA USA;

CBDD Vancouver WA USA;

Pharmacokinet &

Drug Metab PKDM Seattle WA USA;

PKDM ARM Seattle WA USA;

PKDM ARM Seattle WA USA;

Clin Pharmacol Modeling &

Simulat Thousand Oaks CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Generalizable systems pharmacology model of bispecific T-cell engager (BiTE (R)) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients [J] . Chudasama Vaishali L., Harrold John M., Dos Santos Cedric, Journal of pharmacokinetics and pharmacodynamics . 2018,第Suppla期

机译：双特异性T细胞参与者（咬合（r））抗体构建体的概括性系统药理学模型：非霍奇金淋巴瘤（NHL）患者的Blinatumomab（CD19 / CD3）的病例研究
2. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [J] . Goebeler Maria-Elisabeth, Knop Stefan, Viardot Andreas, Journal of Clinical Oncology . 2016,第10期

机译：双特异性T细胞参录（咬合）抗体构建Blinatumomab用于治疗复发/难治性非霍奇金淋巴瘤的患者：我研究的一期的最终结果
3. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis [J] . Yu Jian, Wang Wen, Huang He Hematology. . 2019,第1期

机译：双特异性T细胞参录（咬合）抗体Blinatumab用于治疗复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：全身评测和荟萃分析
4. Design and Characterization of Bispecific Chemically Self-Assembled Antibody Nanoring(CSAN) T-Cell Engagers That Target CD22+ B- Leukemias or Lymphomas [C] . Jingjing Shen, Adrian Fegan, Daniel A. Vallera, PEGS . 2015

机译：靶向CD22 + B-白血病或淋巴瘤的双特化学自组装抗体纳米（CSAN）T细胞啮合的设计与表征
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. A multicenter phase 1 study of solitomab (MT110 AMG 110) a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct in patients with refractory solid tumors [O] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, 2018

机译：索利妥单抗（MT110AMG 110）是双特异性EpCAM / CD3 T细胞衔接子（BiTE®）抗体构建物的多中心1期研究用于难治性实体瘤患者
7. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis [O] . Jian Yu, Wen Wang, He Huang 2018

机译：双特异性T细胞参与者（咬合）抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统性评论和荟萃分析

Generalizable systems pharmacology model of bispecific T-cell engager (BiTE (R)) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients

著录项

相似文献

相关主题

期刊订阅